Skip to main content

Table 5 Baseline characteristics among patients who prematurely discontinued and patients who completed the study

From: Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study

Characteristic Patients with premature discontinuation (N = 34) Patients completing the study (N = 109)
Age, years   
 Mean (SD) 38.8 (10.7) 41.9 (11.6)
 Median (range) 36 (21–64) 42 (21–79)
Gender, n (%)   
 Women 26 (76.5) 73 (67.0)
 Men 8 (22.5) 36 (33.0)
Duration of disease, months N = 26 N = 76
 Mean (SD) 44.8 (60.7) 61.6 (76.5)
 Median (range) 24.8 (0.0–274.9) 33.6 (0.0–372.6)
EDSS, median (range)) N = 28 N = 96
  2.3 (0–6.0); 2.0 (0–6.5);
Previous treatment, n (%)   
 Betaferon® 30 (88.2) 76 (69.7)
 Other treatment 2 (5.9) 4 (3.7)
 No previous treatment 2 (5.9) 29 (26.6)
Previous usage of auto-injector for Betaferon® treatment among patients who received Betaferon® previously, n (%) N = 30 N = 76
 Any 23 (76.7) 61 (80.3)
  BETACOMFORT® 15 (60.0) 36 (59.0)
  BETAJECT Comfort® 8 (32.0) 12 (19.7)
  BETAJECT lite® - 3 (4.9)
  Other  - 10 (16.4)
BETAPLUS® participation, n (% of FAS) 26 (76.5) 61 (56.0)
  1. SD standard deviation, EDSS expanded disability symptom scale, FAS full analysis set